natgillin/translations-raw huggingface dataset:
Distinguishing between field strains and the vaccine strain of M. synoviae can be performed by Hammond classification or High Resolution Melt (HRM) testing by a laboratory. 
Ločevanje med terenskimi in vakcinalnimi sevi M. synoviae se lahko izvede s Hammondovo klasifikacijo ali z analizo talilne krivulje visoke ločljivosti (HRM) v laboratoriju.
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Evropske agencije za zdravila (http://www.ema.europa.eu/)
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LDPE BOTTLE 30 ml LABEL 
NALEPKA NA STEKLENIČKI LDPE 30 ml
Ocular use 
Okularna uporaba
Modified Frey's medium containing phenol red and swine serum 
Druge sestavine: Prirejeno Freyevo gojišče s fenol rdeče in svinjskim serumom
• Infection with M. synoviae induces a transient positive antibody response to Mycoplasma gallisepticum. 
• Okužba z M. synoviae povzroči prehodno pozitiven odziv protiteles na Mycoplasma gallisepticum.
Pharmacotherapeutic group: immunologicals for Aves, live bacterial vaccines ATCvet code: QI01AE03 
Farmakoterapevtska skupina: Imunološka zdravila za ptice, živa bakterijska cepiva.
One dose (30 µl) contains: Mycoplasma synoviae strain MS-H live attenuated thermosensitive, at least 105.7 CCU* 
sev bakterije Mycoplasma synoviae MS-H, živ oslabljen toplotno občutljiv, vsaj 105.7 CCU*
Pullets should first be tested for M. synoviae infection. 
Kokoši je treba predhodno testirati na okužbo z M. synoviae.
Name and address of the manufacturer of the biological active substance 
Ime in naslov proizvajalca (proizvajalcev) biološke (bioloških) učinkovine (učinkovin) Glenorie Manufacturing Facility
Vaccine should not be stored back in -70°C after storage at or below -18°C. 
Po shranjevanju pri temperaturi -18 °C ali manj se cepivo ne sme ponovno shraniti pri temperaturi -70 °C .
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Evropske agencije za zdravila http://www.ema.europa.eu/.
Infection with M. synoviae induces a transient positive antibody response to Mycoplasma gallisepticum. 
Okužba z M. synoviae povzroči prehodno pozitiven odziv protiteles na Mycoplasma gallisepticum.
Vaccination should be carried out on MS-free birds at least 4 weeks before expected exposure to virulent MS. 
Pri pticah brez M. synoviae je treba cepljenje izvesti vsaj štiri tedne pred pričakovano izpostavljenostjo virulentni M.
• Remove the aluminium seal and rubber stopper before using a plastic dropper tip or other administration device. 
• Pred uporabo plastičnega vrha kapalke ali druge naprave za dajanje zdravila odstranite aluminijevo zaporko in gumijasti zamašek.
To avoid skin and eye injuries which may occur by manipulating the frozen bottle, personal protective equipment consisting of gloves and safety glasses should be worn. 
Posebni varnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Za preprečevanje poškodb kože in oči, do katerih lahko pride pri uporabi zamrznjene steklenice, nosite osebno zaščitno opremo, ki sestoji iz rokavic in varnostnih očal.
Only flocks with no antibodies to M. synoviae should be vaccinated. 
Cepiti je treba samo jate, ki nimajo protiteles za M. synoviae.
• Only flocks with no antibodies to MS (M. synoviae) should be vaccinated. 
• Cepiti je treba samo jate, ki nimajo protiteles za M. synoviae.
Remove the aluminium seal and rubber stopper before using a plastic dropper tip or other administration device. 
Pred uporabo plastičnega vrha kapalke ali druge naprave za dajanje zdravila odstranite aluminijevo zaporko in gumijasti zamašek.
• Pullets should first be tested for MS infection. 
• Kokoši je treba predhodno testirati na okužbo z M. synoviae.
Do not use antibiotics with anti-Mycoplasma activity 2 weeks before or 4 weeks after vaccination. 
Dva tedna pred cepljenjem in 4 tedne po njem ne uporabljajte antibiotikov, ki delujejo protimikoplazmam.
MS-H Vaccine eye drops suspension 
Cepivo MS-H, kapljice za oko, suspenzija
One dose of 30 µl to be administered by eye drop. 
En odmerek 30 µl se da kot kapljica v oko.
PACKAGE LEAFLET: MS-H Vaccine eye drops suspension 
NAVODILO ZA UPORABO Cepivo MS-H, kapljice za oko, suspenzija
Batch{number} 
Serija {številka}
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE
TARGET SPECIES 
CILJNE ŽIVALSKE VRSTE Piščanci.
OTHER INFORMATION 
KLINIČNI PODATKI
These signs generally resolve without treatment and within one day. 
Ti znaki običajno izginejo brez zdravljenja v enem dnevu.
The European Commission granted a marketing authorisation valid throughout the European Union, for Certifect on 6 May 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Certifect, veljavno po vsej Evropski uniji, odobrila dne 6. maja 2011.
Gloves are recommended. 
Priporočljiva je uporaba rokavic.
Other information about Certifect: 
Druge informacije o zdravilu Certifect:
People applying the medicine should not smoke, eat or drink, and should wash their hands thoroughly after use. 
Oseba, ki nanaša zdravilo, ne sme kaditi, jesti ali piti, po uporabi pa si mora temeljito umiti roke.
Certifect must not be used on rabbits and cats. 
Zdravilo se ne sme uporabljati pri zajcih in mačkah.
The medicine should be applied in a well-ventilated area. 
Zdravilo nanesite v dobro prezračenem prostoru.
The effectiveness was measured by counting the numbers of ticks and fleas on the dogs five to eight weeks after treatment. 
Učinkovitost so merili s štetjem števila klopov in bolh na psih pet do osem tednov po zdravljenju.
Certifect should not be allowed to enter surface water, as it may be harmful for aquatic organisms. 
Zdravilo Certifect ne sme priti v površinsko vodo, ker je lahko nevarno za vodne organizme.
Studies were also carried out to look at the effect of shampooing on the effectiveness of the medicine. 
Izvedene so bile tudi študije, s katerimi so proučevali vpliv šamponiranja na učinkovitost zdravila.
The active substances in Certifect act as ‘ectoparasiticides'. 
Zdravilne učinkovine v zdravilu Certifect delujejo kot „ektoparaziticidi“.
Children should not be allowed to play with the treated dogs until the application site is dry. 
Otroci se ne smejo igrati z zdravljenim psom, dokler mesto nanosa ni suho.
The effectiveness of Certifect against ticks and fleas was investigated in both laboratory and field studies. 
Učinkovitost zdravila Certifect proti klopom in ušem so proučevali v laboratorijskih in terenskih študijah.
Dogs may lack energy, show lack of muscle coordination, vomit, have a loss of appetite, diarrhoea, salivate, have blood sugar levels higher than normal, be more sensitive to stimulation, and have a slow heartbeat or slow breathing. 
Pri psih se lahko pojavijo tudi pomanjkanje energije, znaki slabe koordinacije mišic, bruhanje, izguba teka, driska, slinjenje, višja raven sladkorja v krvi od običajne, povečana občutljivost na dražljaje in upočasnjeno bitje srca ali upočasnjeno dihanje.
What benefit has Certifect shown during the studies? 
Kakšne koristi je zdravilo Certifect izkazalo med študijami?
Certifect must not be used on sick (e.g. with systemic diseases such as diabetes, or with a fever) or recovering animals. 
Zdravilo Certifect se ne sme uporabljati pri bolnih (s sistemsko boleznijo, kot je diabetes, ali povišano telesno temperaturo) ali okrevajočih živalih.
What is the risk associated with Certifect? 
Kakšna tveganja so povezana z zdravilom Certifect?
Certifect is a medicine that contains three active substances, fipronil, (S)-methoprene and amitraz. 
Certifect je zdravilo, ki vsebuje tri zdravilne učinkovine: fipronil, (S)-metopren in amitraz.
This medicine can cause skin sensitisation and allergic reactions, and people with known allergy to any of the ingredients should avoid contact with the pipette contents. 
Zdravilo lahko povzroči povečano občutljivost kože in alergijske reakcije; osebe z znano alergijo na katero koli sestavino se morajo izogibati stiku z vsebino merilne kapalke.
Treatment should be repeated every month throughout the tick and/or flea seasons. 
Zdravljenje je treba med sezono klopov in bolh ponoviti vsak mesec
This means that they kill parasites that live on the skin or in the fur of animals, such as ticks, fleas and lice. 
To pomeni, da uničujejo zajedavce, ki živijo na koži ali dlaki živali, kot so klopi, bolhe in uši.
(S)Methoprene is absorbed into flea eggs or larvae, where it stops their development. 
(S)-metopren se absorbira v jajčeca ali ličinke bolh in zaustavi njihov razvoj na tej stopnji.
Amitraz stimulates the nervous system of ticks, leading to hyperactivity and death of the ticks. 
Amitraz spodbuja živčni sistem klopov, kar povzroča njihovo hiperaktivnost in smrt.
The studies showed that the effect of Certifect is comparable to that of the combination of fipronil with (S)-methoprene in reducing tick and flea counts in dogs. 
Študije so pokazale, da je učinek zdravila Certifect primerljiv s kombinacijo fipronila in (S)-metoprena pri zmanjševanju števila klopov in bolh pri psih.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Certifect outweigh the risks for the approved indications and recommended that Certifect be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da koristi zdravila Certifect odtehtajo z njim povezana tveganja, kadar se zdravilo uporablja za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
No studies of Certifect in the treatment of lice were presented, as field studies previously presented for the medicine containing fipronil and (S)methoprene were considered sufficient. 
Predstavljene niso bile nobene študije glede uporabe zdravila Certifect za zatiranje uši, saj se je štelo, da zadostujejo predhodno izvedene terenske študije, ki so bile predstavljene za zdravila, ki vsebujejo fipronil in (S)-metopren.
In the main field study, dogs of various breeds, age groups, gender and different weights were treated with either Certifect or a similar ‘spot-on' medicine containing fipronil and (S)-methoprene. 
V glavni terenski študiji so pse različnih pasem, starostnih skupin, spola in različnih telesnih mas zdravili z zdravilom Certifect ali podobnim zdravilom za kožni nanos, ki vsebuje fipronil in (S)-metopren.
In addition, it has been shown that ticks detach more quickly from treated dogs, which indirectly reduces the risk of transmission of certain tickborne diseases to dogs from infected ticks. 
Poleg tega je bilo dokazano, da klopi prej odpadejo z zdravljenih psov, kar posredno zmanjšuje tveganje za prenos nekaterih s klopi prenosljivih bolezni, ki se prenašajo z okuženih klopov na pse.
The medicine can be used in the management of flea allergy dermatitis (an allergic reaction to flea bites). 
Zdravilo se lahko uporablja tudi pri zdravljenju alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
It is available as a ‘spot-on' solution in pipettes already filled with the correct amount needed to treat one dog depending on its weight. 
Na voljo je v obliki raztopine za kožni nanos v merilnih kapalkah, predhodno napolnjenih z ustrezno količino zdravila, potrebnega za zdravljenje enega psa glede na njegovo telesno maso.
Certifect is used in dogs to treat and prevent infestations with ticks and fleas, and to treat infestations with chewing lice. 
Zdravilo Certifect se uporablja pri psih za zdravljenje in preprečevanje infestacij s klopi in bolhami ter za zdravljenje infestacij z zajedavskimi ušmi.
Other studies were performed to investigate if Certifect reduced the risk of transmission of certain tick-borne diseases. 
Druge študije so bile izvedene, da bi se ugotovilo, ali zdravilo Certifect zmanjšuje tveganje za prenos nekaterih s klopi prenosljivih bolezni.
Contact with the application site should be avoided. 
Izogibati se je treba stika z mestom nanosa.
The content of one full Certifect pipette (appropriate to the dog's weight) is applied directly to the dog's skin, after parting its fur, in two separate spots (halfway down the back of the neck, and at the base of the neck). 
Vsebina ene polne merilne kapalke zdravila Certifect se (glede na telesno maso psa) nanese neposredno na kožo psa, tako da se razmakne dlaka in se zdravilo nanese na dve različni mesti (na zgornji del hrbta in na zatilje).
Both fipronil and amitraz kill adult parasites while (S)-methoprene kills parasites at the egg or larval stage. 
Fipronil in amitraz uničujeta odrasle zajedavce, (S)-metopren pa uničuje zajedavce v fazi jajčeca ali ličinke.
If accidental exposure to the eyes occurs, the eyes should be rinsed with water and in case of accidental exposure to the skin the skin should be washed with soap and water. 
V primeru nenamerne izpostavitve oči zdravilu Certifect, je treba oči nemudoma temeljito izprati z vodo, v primeru nenamerne izpostavitve kože, pa to umiti z vodo in milom.
Dogs may show some temporary reactions at the site of application (skin discolouration, hair loss, itching or redness). 
Lahko se pojavijo začasne reakcije na mestu nanosa (razbarvanje kože, izpadanje dlake, srbenje ali rdečica).
Fipronil works on channels in the cells of the nervous system of ticks and fleas, blocking the transfer of ions in and out of cells, 
Fipronil deluje na kanale v celicah živčnega sistema klopov in bolh ter zavira prenos ionov v celice in iz njih, kar povzroča nenadzorovano delovanje osrednjega živčnega sistema in smrt teh zajedavcev.
What is Certifect used for? 
Za kaj se zdravilo Certifect uporablja?
For a full list of all side effects reported with Certifect, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Certifect, glejte navodilo za uporabo.
If side effects are seen, immediate medical assistance should be sought and the package leaflet or label shown to the doctor. 
Če se pojavijo neželeni učinki, se je treba nemudoma posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali ovojnino.
How has Certifect been studied? 
Kako je bilo zdravilo Certifect raziskano?
What is Certifect? 
Kaj je zdravilo Certifect?
How does Certifect work? 
Kako zdravilo Certifect deluje?
Influenza virus surface antigens*, inactivated: A/Vietnam/1194/2004 (H5N1) - like strain used (NIBRG-14) 7.5 micrograms** per 0.5 ml dose * propagated in eggs ** expressed in microgram haemagglutinin. 
Površinski antigeni virusa influence*, inaktivirani: uporabljen sevu A/Vietnam/1194/2004 (H5N1) - podoben sev, (NIBRG-14) 7,5 mikrogramov** na 0,5 ml odmerka * razmnožen v jajcih ** izraženo v mikrogramih hemaglutinina
Packaging Content (concentration) Package size 
Vsebina Velikost pakiranja
If taken without food the medicine may not work properly. 
Če se zdravilo vzame brez hrane, morda ne bo pravilno delovalo.
The recommended dose is four capsules three times a day (a total of 12 capsules a day). 
Priporočeni odmerek je štiri kapsule trikrat na dan (skupaj 12 kapsul na dan).
This is a summary of the European public assessment report (EPAR) for Victrelis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Victrelis.
The full EPAR for Victrelis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Victrelis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It should be taken with food (a meal or light snack). 
Zdravilo se mora jemati skupaj s hrano (obrokom ali lahkim prigrizkom).
However, the Committee decided that the medicine's benefits outweighed its risk and recommended that it be granted marketing authorisation. 
Odbor je kljub temu menil, da so koristi zdravila večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What measures are being taken to ensure the safe use of Victrelis? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Victrelis?
The company that makes Victrelis will ensure that all doctors expected to prescribe the medicine are provided with an educational pack with detailed information on the medicine, including information on the risk of anaemia and other side effects. 
Družba, ki izdeluje zdravilo Victrelis, bo zagotovila, da bodo vsi zdravniki, ki naj bi predpisovali to zdravilo, prejeli izobraževalni paket z natančnimi informacijami o zdravilu, vključno z informacijami o tveganju za anemijo in drugih neželenih učinkih.
For a list of these medicines see the summary of product characteristics (also part of the EPAR). 
Za celoten seznam teh zdravil glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
When the enzyme is blocked, the virus does not replicate normally and this slows down the rate of replication, helping to eliminate the virus. 
Z zaustavitvijo delovanja encima se virus ne more normalno razmnoževati, kar upočasni hitrost njegovega razmnoževanja in pomaga pri uničevanju virusa.
What benefit has Victrelis shown during the studies? 
Kakšne koristi je zdravilo Victrelis izkazalo med študijami?
These medicines can be harmful at high levels in the blood and it is important to avoid taking them when taking Victrelis. 
Ta zdravila so lahko škodljiva, kadar so v krvi prisotna v visokih koncentracijah, zato je pomembno, da jih med zdravljenjem z zdravilom Victrelis ne jemljete.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Victrelis, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev
Two main studies involving 1,099 previously untreated and 404 previously treated patients with chronic hepatitis C genotype 1 infection and compensated liver disease were carried out. 
Izvedeni sta bili dve glavni študiji, v kateri je bilo vključenih 1 099 predhodno nezdravljenih bolnikov in 404 predhodno zdravljeni bolniki z okužbo s kroničnim hepatitisom C genotipa 1 in s kompenzirano boleznijo jeter.
It must not be used in patients with autoimmune hepatitis (hepatitis caused by an immune disorder) or in pregnant women. 
Ne smejo ga uporabljati bolniki z avtoimunskim hepatitisom (hepatitisom, ki ga povzročajo obolenja imunskega sistema) ali nosečnice.
Victrelis is to be used in patients with compensated liver disease who have not been treated before or whose previous treatment has failed. 
Zdravilo Victrelis se uporablja pri bolnikih s kompenzirano boleznijo jeter, ki še niso bili zdravljeni ali pri katerih predhodno zdravljenje ni bilo uspešno.
Victrelis was also shown to be effective in some patients whose treatment was shortened following blood tests in which the virus could no longer be detected in their blood. 
Zdravilo Victrelis se je izkazalo kot učinkovito tudi pri nekaterih bolnikih, pri katerih je bilo zdravljenje skrajšano zaradi izvidov krvnih preiskav, ki so pokazale, da v krvi ni več zaznanega virusa.
The effects of Victrelis were first tested in experimental models before being studied in humans. 
Učinki zdravila Victrelis so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri
Why has Victrelis been approved? 
Zakaj je bilo zdravilo Victrelis odobreno?
Victrelis can slow down the rate at which certain medicines are broken down in the liver. 
Zdravilo Victrelis lahko upočasni hitrost razkrajanja nekaterih zdravil v jetrih.
The European Commission granted a marketing authorisation valid throughout the European Union for 
Evropska komisija je dovoljenje za promet z zdravilom Victrelis, veljavno po vsej Evropski uniji,
The main measure of effectiveness was the number of patients who had no detectable virus in their blood 24 weeks after the end of the treatment and could therefore be 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih 24 tednov po zaključku zdravljenja v krvi ni bilo zaznanega virusa, kar
It blocks an enzyme called HCV NS3 protease, which is found on the hepatitis C virus of the type 1 genotype and is involved in the virus's replication. 
Zavira encim, imenovan proteaza HCV NS3, ki je prisoten na virusu hepatitisa C genotipa 1 in vpliva na razmnoževanje virusa.
The other most common side effects with Victrelis are fatigue (tiredness), nausea (feeling sick), headache and dysgeusia (taste disturbances). 
Drugi najpogostejši neželeni učinki pri uporabi zdravila Victrelis so utrujenost, navzeja (slabost), glavobol in disgevzija (motnje okušanja).
For more information about treatment with Victrelis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Victrelis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Victrelis? 
Kakšna tveganja so povezana z zdravilom Victrelis?
In the study of previously untreated patients, 66% of patients who received Victrelis for 44 weeks (242 out 366) were cured compared with 38% of those who received placebo (137 out of 363). 
V študiji s predhodno nezdravljenimi bolniki je bilo ozdravljenih 66 % (242 od 366) bolnikov, ki so 44 tednov prejemali zdravilo Victrelis, v primerjavi z 38 % (137 od 363) tistih, ki so prejemali placebo.
All patients also received peginterferon alfa and ribavirin. 
Vsi bolniki so prejemali tudi peginterferon alfa in ribavirin.
Victrelis must not be used in people who are hypersensitive (allergic) to boceprevir or any of the other ingredients. 
Zdravila Victrelis ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) boceprevir ali katero koli drugo sestavino zdravila.
Victrelis is a medicine that contains the active substance boceprevir. 
Victrelis je zdravilo, ki vsebuje zdravilno učinkovino boceprevir.
The active substance in Victrelis, boceprevir, is a protease inhibitor. 
Zdravilna učinkovina zdravila Victrelis, boceprevir, je zaviralec proteaze.
In both studies Victrelis was compared with placebo (a dummy treatment). 
Zdravilo Victrelis so v obeh študijah primerjali s placebom (zdravilom brez zdravilne učinkovine).
In a second study in patients in whom previous treatment had failed, the cure rate was 67% (107 out of 161) for patients who received Victrelis for 44 weeks compared with 21% (17 out of 80) for those 
V drugi študiji, v katero so bili vključeni bolniki, pri katerih predhodno zdravljenje ni bilo uspešno, je bilo ozdravljenih 67 % (107 od 161) bolnikov, ki so 44 tednov prejemali zdravilo Victrelis, v primerjavi z 21 % (17 od 80) bolnikov, ki so prejemali placebo.
Compensated liver disease is when the liver is damaged but is 
Kompenzirana bolezen jeter pomeni, da so jetra poškodovana, vendar še vedno lahko normalno delujejo.
Treatment with Victrelis should be started and monitored by a doctor experienced in managing chronic 
Zdravljenjem z zdravilom Victrelis mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem
It is available as capsules 
Na voljo je v obliki kapsul (200 mg).
For more information on how to use Victrelis, including its combination with peginterferon alfa and ribavirin and the length of treatment, see the summary of product characteristics (also part of the EPAR). 
Več informacij o načinu uporabe zdravila Victrelis, pa tudi glede kombinacije s peginterferonom alfa in ribavirinom ter trajanja zdravljenja, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
For the full list of all side effects reported with Victrelis, see the 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Victrelis, glejte navodilo za uporabo.